The Changing Outlook for Immunotherapies in Cancer Treatment
Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.
Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.
Recently, Kaufman says, immunotherapies have been meeting their endpoints in clinical trials and are being associated with durable responses. Further, immunotherapies seem to demonstrate overall survival benefit, which is completely changing the outlook for the class of agents. Immunotherapies are gaining more widespread support and acceptance.
Clinical Pearls
There remains a need for more research to understand the mechanisms of immunotherapies and to identify predictive biomarkers to get appropriate patients into studies sooner. Researchers are also looking at a vast array of potential combinations of immunotherapies.
- Immunotherapies have been meeting endpoints in clinical trials and seem to be demonstrating overall survival benefit
- There is a need for more research into immunotherapies to understand how they work and to identify predictive biomarkers
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
